40% 71% 72% 67% 40% of respondents said they were very familiar with biosimilars, 51% said they were only slightly familiar with biosimilars 72% reported that they were likely to prescribe biosimilars if/when they become available in the US, 49% said they were very likely 71% claimed they were likely to prescribe an interchangeable biosimilar, while only 59% would prescribe a non-interchangeable one 67% of gastroenterologists surveyed favor prohibition of indication extrapolation in approval of biosimilars for IBD In response to biosimilar standards, quality, and safety: biosimilars.us | What Do Gastroenterologists Think? What Do Gastroenterologists Think? 80% are very concerned about clinical similarity between the biosimilar and reference product in regards to effectiveness and safety 78% of respondents are very concerned about the immunogenicity and safety of biosimilars 55% of the gastroenterologists surveyed feel pharmacy level substitution should only be permitted with notification of prescriber 35% believe pharmacy level substitution should be ruled out all together When considering the use of a biosimilar: 80% 78% 55% 35% 69% said their reasoning is lack of experience with biosimilars 65% said more time is needed to examine the effectiveness of biosimilars Out of those who said they were unlikely to prescribe biosimilars: 69% 65% Source: Gastro.org,. 'National Survey Reveals Gastroenterologists' Views On Biosimilar Drugs'. N.p., 2015. Web. 17 Aug. 2015. In late July, the American Gastroenterological Association released findings from a national survey of gastroenterologists on biosimilars and biologics. Biologics are used regularly for the treatment of inflammatory bowel disease (IBD), and biosimilars for the treatment of IBD, such as Remsima/Inflectra are globally on the rise. This survey reveals that many gastroenterologists are concerned about the safety and efficacy of biosimilars and that some are still unfamiliar with the type of drug itself.

What Do Gastroenetrologists Think About Biosimilars?

Download PDF Report

Upload
small-world-social
View
432
Download
0

Embed Size (px)

Citation preview

Page 1: What Do Gastroenetrologists Think About Biosimilars?

40%

71%

72%

67%

40% of respondents said they were very familiar with biosimilars, 51% said they were only slightly familiar with biosimilars

72% reported that they were likely to prescribe biosimilars if/when they become available in the US, 49% said they were very likely

71% claimed they were likely to prescribe an interchangeable biosimilar, while only 59% would prescribe a non-interchangeable one

67% of gastroenterologists surveyed favor prohibition of indication extrapolation in approval of biosimilars for IBD

In response to biosimilar standards, quality, and safety:

biosimilars.us | What Do Gastroenterologists Think?

What Do Gastroenterologists Think?

80% are very concerned about clinical similarity between the biosimilar and reference product in regards to effectiveness and safety

78% of respondents are very concerned about the immunogenicity and safety of biosimilars

55% of the gastroenterologists surveyed feel pharmacy level substitution should only be permitted with notification of prescriber

35% believe pharmacy level substitution should be ruled out all together

When considering the use of a biosimilar:

80% 78%

55% 35%

69% said their reasoning is lack of experience with biosimilars

65% said more time is needed to examine the effectiveness of biosimilars

Out of those who said they were unlikely to prescribe biosimilars:

69% 65%

Source:Gastro.org,. 'National Survey Reveals Gastroenterologists' Views On Biosimilar Drugs'. N.p., 2015. Web. 17 Aug. 2015.

In late July, the American Gastroenterological Association released findings from a national survey of gastroenterologists on biosimilars and biologics. Biologics are used regularly for the treatment of inflammatory bowel disease (IBD), and biosimilars for the treatment of IBD, such as Remsima/Inflectra are globally on the rise.

This survey reveals that many gastroenterologists are concerned about the safety and efficacy of biosimilars and that some are still unfamiliar with the type of drug itself.

http://biosimilars.us